Xin Mu, MD, MS Clinical Research Coordinator UCSF Profile Publications EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy. Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. Identification of breast cancer subtypes and drug response prediction through forward and reverse translation. Photoproximity labeling of c-Myc reveals SLK as a cancer specific co-regulator. Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors. Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia. See All Publications
